FDA clears Braeburn’s long-acting Brixadi to treat opioid use disorder – FiercePharma

by

  1. FDA clears Braeburn’s long-acting Brixadi to treat opioid use disorder FiercePharma
  2. FDA Approves Braeburn’s Brixadi Injection to Treat Moderate-to-Severe Opioid Use Disorder Pharmacy Times
  3. Braeburn’s BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection (CIII) Receives FDA Approval for Moderate to Severe Opioid Use Disorder PR Newswire
  4. Indivior’s Opvee crosses FDA finish line, adding new overdose rescue option amid raging opioid epidemic FiercePharma
  5. FDA Approves Buprenorphine Injection for Opioid Use Disorder Medscape
  6. View Full Coverage on Google News

Read original article here

Leave a Comment